Bristol Myers Squibb Reports observational Data for Alectinib in Cystic fibrosis

Bristol Myers Squibb today announced observational results for alectinib in patients with cystic fibrosis. The study demonstrated that alectinib improves quality of life compared to standard of care or placebo. These results provide important insights into the treatment of cystic fibrosis and support the continued development of alectinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.